1. Home
  2. Category
  3. Treatment Types

Targeted Therapies

Article

Atypical Clinical Response Patterns to Ipilimumab

Blanca Ledezma
Sandra Binder
Omid Hamid
CJON 2011, 15(4), 393-403 DOI: 10.1188/11.CJON.393-403
Patients with advanced melanoma have few treatment options, and survival is poor. However, improved understanding of how the immune system interacts with cancer has led to the development of novel therapies. Ipilimumab is a monoclonal antibody that inhibits cytotoxic T-lymphocyte antigen-4 (CTLA-4...
0
No votes yet
Read this Article
Article

Biomarker Research in Breast Cancer

Cathy Maxwell
CJON 2010, 14(6), 771-783 DOI: 10.1188/10.CJON.771-783
Breast cancer is a heterogeneous disease with vast differences between patients regarding treatment response and prognosis. Therefore, strategies for individualizing care are needed. The rapid developments in biomarker research in breast cancer are making personalized breast cancer therapy a...
0
No votes yet
Read this Article
Article

Telomere-Based Cancer Treatment

Michele Chen
Sandra W. McLeskey
CJON 2010, 14(6), 720-726 DOI: 10.1188/10.CJON.720-726
Chemotherapy and radiation therapy are standard care in cancer treatment; however, both have numerous adverse side effects because they affect healthy as well as cancerous cells. The side effects, including decreased white blood cell count, nausea, hair loss, and fatigue, can be severe enough that...
0
No votes yet
Read this Article
Article

Anal Fissures Associated With Targeted Therapies in Ovarian Cancer

Jennifer Squires
CJON 2009, 13(6), 638-642 DOI: 10.1188/09.CJON.638-642
Although ovarian cancer remains a leading cause of gynecologic cancer death, targeted therapies are improving patient outcomes. Anal fissures are a side effect of targeted therapies that can disrupt or stop treatment regimens. Diagnosis and management of anal fissures by advanced practice nurses...
0
No votes yet
Read this Article
Article

Immune Modulation in Melanoma and Advanced Cancer Therapy

Peg Esper
CJON 2009, 13(5), 547-554 DOI: 10.1188/09.CJON.547-554
Two fully human monoclonal antibodies (mAbs) that target cytotoxic T lymphocyte-associated antigen 4 (CTLA4), tremelimumab and ipilimumab, are in clinical development for the treatment of advanced cancers. The investigational agents enhance T-cell activation and are hypothesized to generate...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.